Interim report
Page 1
Ajanta Pharma Limited Ajanta Tower, 54-A, M Vasanji Road, Chakala, Andheri (E), Mumbai 400 093, India Corporate Identity Number - L24230MH1979PLC022059 T +91 22 6060 9000 E legal.info@ajantapharma.com W www.ajantapharma.com 30th October 2026 BSE LIMITED Phiroze Jeejeebhoy Towers Dalal Street, Mumbai – 400001 Scrip Code: BSE – AJANTPHARM 532331 National Stock Exchange of India, Exchange Plaza, 5th Floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051 Scrip Code: NSE AJANTPHARM EQ Sub.: Outcome of the Board Meeting Dear Sir/Madam, At the Board meeting held today, the Board has inter -alia approved and taken on record Unaudited Financial Results for the quarter and half year ended 30th September 202 6. Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the following: i. Press Release being issued on the Results for the second quarter and half year ended 30 th September 2026; ii. Unaudited Consolidated Financial Results for the second quarter and half year ended 30th September 2026; iii. Limited Review Report from Auditors M/s. B S R & Co. LLP on the Unaudited Consolidated Financial Results for the second quarter and half year ended 30th September 2026; iv. Unaudited Standalone Financial Results for the second quarter and half year ended 30th September 2026; v. Limited Review Report from Auditors M/s. B S R & Co. LLP on the Unaudited Standalone Financial Results for the second quarter and half year ended 30th September 2026; vi. Investor presentation. Meeting of the Board of Directors commenced at 11.30 a.m. and concluded at 12:50 p.m. Kindly take the above on your records. Thanking You, Yours faithfully, GAURANG SHAH Sr. VP - Legal & Company Secretary Encl.: a/a
Page 2
T +91 22 6060 9000 E corpcom@ajantapharma.com W www.ajantapharma.com Ajanta Pharma Limited Ajanta Tower, 54-A, M Vasanji Road, Chakala, Andheri (E), Mumbai – 400 093, India Corporate Identity Number - L24230MH1979PLC022059 Press Release Revenue up by 33% and PAT up by 49% (2nd Quarter FY 2027 Consolidated Results) Mumbai, 30th October, 2026: Ajanta Pharma Ltd., a specialty pharmaceutical formulation company today reported its excellent performance for 2nd quarter, and half year ended 30th September 2026. Q2 FY 2027 performance highlights (compared to Q2 FY 2026): • Revenue from operations at Rs. 1,794 cr. against Rs. 1,354 cr.; up 33%. • Adjusted EBITDA (excluding forex loss) at Rs. 543 cr. & 30% against Rs. 369 cr., up 47%. • Profit after tax at Rs. 388 cr. against Rs. 260 cr.; PAT at 22%; up 49%. H1 FY 2027 performance highlights (compared to H1 FY 2026): • Revenue from operations at Rs. 3,420 cr. against Rs. 2,656 cr.; up 29%. • Adjusted EBITDA (excluding forex loss) at Rs. 997 cr. & 29% against Rs. 745 cr., up 34%. • Profit after tax at Rs. 722 cr. against Rs. 516 cr.; PAT at 21%; up 40%. • ROCE stood at a healthy level of 41% and RONW at 31%. Segment wise performance: (Rs. cr.) Markets Q2 Gwth% H1 Gwth% FY 2026 FY 2027 FY 2026 FY 2027 Branded Generics India ₹ 432 ₹ 504 16% ₹ 841 ₹ 1,013 20% Asia ₹ 310 ₹ 366 18% ₹ 614 ₹ 621 1% Africa ₹ 221 ₹ 312 41% ₹ 449 ₹ 607 35% Sub-Total ₹ 963 ₹ 1,182 23% ₹ 1,904 ₹ 2,241 18% US Generic ₹ 344 ₹ 484 41% ₹ 653 ₹ 971 49% Africa Institution ₹ 32 ₹ 116 259% ₹ 71 ₹ 187 164% Total ₹ 1,339 ₹ 1,782 33% ₹ 2,628 ₹ 3,399 29% As per IQVIA MAT September 2026, our India branded generic performance exceeded IPM growth by 27%. The higher growth came from new launches, which exceeded IPM by 70% & volumes, which exceeded IPM by 18%.
Page 3
T +91 22 6060 9000 E corpcom@ajantapharma.com W www.ajantapharma.com Ajanta Pharma Limited Ajanta Tower, 54-A, M Vasanji Road, Chakala, Andheri (E), Mumbai – 400 093, India Corporate Identity Number - L24230MH1979PLC022059 India branded generic segment wise performance as per IQVIA MAT September 2026 against IPM is as below: Therapy Growth % IPM Ajanta Cardiology 17% 13% Ophthalmology 12% 18% Dermatology 11% 14% Pain Management 13% 16% Overall 13% 17% Though our Cardiology growth looks lower than IPM as per IQVIA due to some anomaly in the working, our internal growth is at par with the IPM. ANDA status as at the end of H1 FY 2027 is as below: Particulars H1 FY 2027 Filed 1 Approval received 4 Launched 3 Total ANDA's commercialized 52 Awaiting approval with US FDA 17 Tentative approval 5 R&D expense: (Rs. cr.) Particulars FY 2026 FY 2027 % to Revenue Q2 ₹ 63 ₹ 72 4% H1 ₹ 119 ₹ 138 4% About Ajanta Pharma Limited Ajanta Pharma is a speciality pharmaceutical formulation company having major focus on branded generic business across India, Asia & Africa. Company has ground presence in each of these 34+ countries. Many of company’s products are 1st to market and are leading in their sub-therapeutic segments. Company also has presence in USA in generic business and institution business in Africa. Company’s state of the art R&D centre is in Mumbai. Company has 7 world class manufacturing facilities located in India. For the last 3 financial years, company has posted healthy Revenue and PAT CAGR of 14%.
Page 4
T +91 22 6060 9000 E corpcom@ajantapharma.com W www.ajantapharma.com Ajanta Pharma Limited Ajanta Tower, 54-A, M Vasanji Road, Chakala, Andheri (E), Mumbai – 400 093, India Corporate Identity Number - L24230MH1979PLC022059 Earnings Conference Call The Company will host an Earnings Conference Call at 16:00 hrs. IST (18:30 hrs. SST/HKT, 10:30 hrs. GMT, 06:30 hrs. US ET), during which the leadership team will discuss the financial performance and take questions. A transcript of the conference call will be available at www.ajantapharma.com. Dial-in Information Date and Time October 30, 2026 at 16:00 – 17:00 hrs IST 18:30 – 19:30 hrs SST/HKT 10:30 – 11:30 hrs GMT 06:30 – 07:30 hrs US ET Dial-in Numbers Diamond pass link for faster access Click here to register Universal Access Primary Access: (+91 22 6280 1542) (+91 22 7115 8372) International Toll Free USA: 18667462133 UK: 08081011573 Hong Kong: 800964448 Singapore: 8001012045 For convenience and faster connectivity to the conference, kindly follow the below steps: 1. Register through the Diamond pass link. 2. You will receive a calendar invite along with a passcode and a PIN number. The passcode and PIN will be activated 30 minutes prior to the conference scheduled time. 3. Dial the ‘conference Dial-in number’ you will receive on your email. 4. On system prompt dial the PASSCODE followed by # key. 5. On system prompt enter the PIN followed by # key. 6. If the line gets disconnected, you need to dial the ‘conference dial -in number’ again and follow the necessary steps. Playback of Earnings Conference Call audio: Playback of the earnings call will be available 120 minutes after the end of the call on our website (www.ajantapharma.com). For more details visit www.ajantapharma.com For regular updates follow us on x.com – https://x.com/AjantaPharmaLtd For specific queries, contact: Rajeev Agarwal Tel: +91 22 6060 9706 Email: rajeev.agarwal@ajantapharma.com Abhineet Kumar Tel: +91 22 6060 9721 Email: abhineet.kumar@ajantapharma.com Reuters: AJPH.NS, Bloomberg: AJP:IN, NSE: AJANTPHARM, BSE: 532331 Corporate Identity Number (CIN): L24230MH1979PLC022059 Safe Harbour Statement
Page 5
@ aianta pharma Ajanta Pharma Limited Ajanta Tower, 54-A, [I V Road, Chakala, Andheri (E), Mumbai - 400 093, lndia T +91 22 6060 9000 E aplfinance@ajantapharma.com W wwwalantapharma.com Statemcnt of Consolidateal Unaudited Financial Results for the quarter and six months ended 30 September 2026 Greot Plqce to Work" Ccrtified 3GSeo-26 3GJ!n 26 3GSeD 25 30 Seo 26 30 Seo-25 Revenue rrom operations Other in@me (Rcrernolo 4) 1,7 .16 37.39 1,625.96 70.90 1,353 73 59 34 3,12012 108 29 2.656.36 85.67 5,452 a5 1t2 07 1,831.55 1,696.86 1,413.07 3.528 41 2,742.05 5,624.93 Cosl ol malerials consumed Purchas€s ol slocl'in-trade Changes in invenlories ol linish€d goods, wo*-in prolress and slock-in lrade Employee b€nefits expense Oepreciation and amortisation exp€nse Olher expeffies (Refe. note,l) 344.97 80.89 14.751 343.69 2.21 47.fi 477.80 296.51 66 92 (3s s8) 341.11 3.18 44 50 493.42 217.60 53 26 45 95 317 01 339 42 97 392.08 645 4a 117.81 (80.33) 764 80 542 92.Cr6 971.22 424.@ 104 69 63 12 619.91 865 84 26 764.50 916.51 229.79 37.46 t,291.15 16.11 173.11 1,583.12 1,296,40 1,250.06 1,072.26 2,546.46 2,07011 1,247.26 160.67 (13 66) 446.80 102.72 9.86 340.81 78 30 2.32 981.95 263.39 (3.80) 671 94 151 80 461 1,377.65 300.06 2t 57 Net Prolit lor the p€riod Other ComprEhsn3lvs lncome {OCl) liems lhatwillbe reclassilied subsequenllyto protlt or loss lncomela( relatinglo ltemsthal willb€ reclsssified subsequentlyto prolii or loss liems lhatwillnol be reclassified subsequenllyto protil or loss lncome tax relatinslo ilems lhatwillnot be reclassiliod to prolit or loss 3EE.1lt 291 2.97 (1.04) (0.94) (5.11) 1.79 260.19 783 072 (0.25) 722.36 1.97 12.14) 075 515.53 11 24 (4.27') 1.49 1,056.00 29.39 (0 48) 017 Other Comorehens lve lncome lor th€ vear. net ol tar 4,44 (4.26\ 8.30 0.58 846 29.08 Total Comprehensive lncome lor the period 392.98 329.96 268.49 523.99 1,085 08 Paid up Equity Share Capilal(Face value ofa 2 each) Other Equity Eamings Per Share (Face value ol a 2 each) (a) Basic - in a (b) Diluled - in I 25 A7 31.07 31 03 25.47 26.75 26.72 25 07 20 83 2A A2 25 A7 57 81 57 76 25 07 41 27 41 26 25 0T 4,502 02 84.53 84 51 have expressed an unmodilied conclusion The review Gpod has been nled with lhe sloct exchange and is available on company w€bsite. (Lisiing Obligalions and oisclosure Requi.efients) Regulalions, 2015, as amended. Therc is no minorily inleresl 3GSetr26 3GJuc26 3GSeo-25 3GSep-26 30-Sep-25 31-Mats26 Foreq. exchanqe qa n { n other income) 23 66 50 47 39 63 69 13 49 01 97 17 Fore€n erchange loss (in olher expense) 30 59 40 95 25 59 66 10 103 04 resuhng ln an increas€ in the paid-up share capilal by I 46,E00 (provious period { 47,050)and securnies premium by I 3.47 clores (prevaous period I 3 50 crores). Corporale ldentity Number - L242301\rH1 979pLC022059 Registered offlce: Ajanta Tower, 54-A, M vasanji Road, chakala, Andheri (E), Mumbai- 400 093. Tel.: +91-22-6060 gooo B $tcs\q \t c
Page 6
@ aianta pharrna Ajanta Pharma Limited Ajanta Tower, 54-A, M V Road, Chakala, Andheri (E), Mumbai - 400 093, India T +91 22 6060 9000 E apllinance@ajantapharma.com W wwwajantapharma.com 6. Statement of Consolidated Assets and Liabilities Greqt Ploce To Work. Certilied 3GSep26 31-Mar-26 ASSETS Prop€rly, plant and equipmenl Capnal work-in-pmgress Other intangible assels Olher linancial assets Delened lar assets (nel) lncome t.x asseis (net) Oth€r no'lstrent assels 1.783 44 326.55 97 16 45 84 32.O7 421 185 35 17 24 106 13 1.726 35 256 05 99 02 41 58 2E.50 7.99 188 59 7.56 61.77 Tot l non{urent assets Cash and c€sh equivalent3 Bank balances olher lhen c63h and cash Bquivalonlr Other linanciel assets 2,601.99 966 58 588.09 1,853.60 90.18 177 1.49 3.44 306.13 2,4'19.41 938 54 559.85 1,853.88 103.26 1.51 1.66 8.98 267.73 Total current assoG 3,823 28 3,735.43 6.425.27 6,154.84 EOUITY ANO LIABILITIES Equity Olhgr equily 25 07 4,833.20 25 A7 4.502 a2 Non.current tiabitttios Olher fl nancial liabililies Olher non-c!rrenl liabililies De,er.ed rax riabirftes (Neo 4,454.27 37.26 2.51 t.50 75 20 107.73 4,527.09 39.42 1.e2 1.67 51 15 117 94 Total Non.current liabilities CuIIlnt llrblllU.r (a) tolal ouBtanding du€s ol micro .nd lmall cntcn i36. (b) lold odstarEirE duca ol credito€ o0l€r than mic.o ar1d lmett crXerpai3os Oth€r linancial liabililica Lease laabilities Ot'er liabililio! lncorne ler liabiliti6! (Nat) 224.20 104 30 44.21 527.O3 125.49 12160 32 38 7518 212.00 211.99 54.17 490.13 495.62 8.76 119.@ 30 39 549 ToGl current tiabitities 1,342.80 1.415.75 1 567.00 1.627.75 4 425.27 6 151.64 Corporate ldentity Number - L24230MH1979pLC022059 Registered Ofiice:A.ianta Tower, 54-A, M Vasanji Road, Chakala, Andheri (E), Mumbai- 400 093. Tet.: +91-22-6060 9OOO id Ce.l iq t0
Page 7
@ phannaaianta Ajanta Pharma Limited Ajanta Tower, 54-A, [,l V Road, Chakala, Andheri (E), Mumbai - 400 093, lndia 7. Statement of Consolidated Cash Flow I n crore Greot Ploceto Work. Certified 30'Sep'26 30-SeE25 31-Mar-26 A. C.!h flow trom opolating acuvitlss Oepreciation and amortisalion expense Loss/ (gain) on sale / retirement of property. planl and equipmert (nel) Loss/ (Gain) on investrnenl al FWPL Loss/ (Gain) on lair value ol denvative Loss/ (Grin) on sale/redemplion ol Curenl lnvestments lnterest income on inveslrnenls and deposils Defened govemmenl granl Eq'rity settled share based payment Unre.lised forcign exchrnge loss / (gain) lmDaiment (Gain) / Ioss on linancialassels 981 95 92.05 038 542 (0 32) (69 13) (6 7E) (29 15) (0 17) 8.10 38 24 u.26 062 6.65 0.35 65.10 (4.75) (23.51) (0.17) o.77 (30.82) 1.41 1.377 65 173.14 187 16.11 (1.ss) 88 92 (8 70) (s1.60) (0 33) 153 (58 14) 221 Operailng c.sh llow berore wo.king c.plt lchrnges Changes in working @pital Deqease / (lnsease) in lade receNables Dec{ease / (hcrease) in oth€r receivable Dec.ease / (lncrease) in inventories (Decr€ase) / lncrease in lrade payable lncrease/ (Oecrease) in other payable lnc.ease / (Oec{ease) In Drovisions 1,020.60 (4e ss) (28 7B) 127.79) 2A 67 l'11.72) 24.61 774.85 \226.Ut (71.89) 93.13 (23.17) (61 13) (44 U 1,541.11 (s90 84) (1s8 82) (30 9s) 90 79 59 26 122 391 Cash 9ene..ted from operating activitlos Nei income la( pad 956.07 (206 ss) 110.41 (156.87) 848.18 (358 99) Nat c.sh g€nerated from operatlng ictlvltles B. C.sh flow trom lnvestlng actlvitlas Capitrl e4enditurc on properly, planl and equipmeni & intangible assels including capilal advancer Prcceeds lrom srle of properly, planl and equipmenl aank balances flot considered as cash and cash equivalents (nel) Purchase oI curenl inveslmenls Prcceeds trom sale ofcuneni investments lncome on rnveshents and deposits lnveslment in Privale Limiled Compaoy/Limded Liabiny Partneslrip - Non Cunent lnv€nmern 749.52 (259.03) o42 (0.26) (2,118.96) 2,097 A2 34.46 (3 57) 283.94 1173.47]- 706 (0.17) (1,560.86) 1,154.99 23 51 529 19 (365.16) 541 (0.3e) (2,659.98) 2.549.09 45 37 (3 26) Net cesh used ln investi n9 .ctiviues C. C.3h aow trom lin.ncing aclivldos Proceeds / (repaymern) or borrowings (net) Payment of lease liability 0ncruder inrsE r o, Rr 1 73 cDc. in cure^r F.r, R. r 62 cmr ri pBiour y.r .nd R. 3 31 c6Bt in Fy 2026) Dividend paid l.249.121 (107.69) (3 e{) t3.77) {399.61) (s48.94) 199 13 (7 03) (10 5E) (0 01 $2a.921 20940 (12.80) (14 80) (u9 72) Net c.sh uied in linancinO activitles Net Incre.se / (decrease) in cash and cesh equlvalenis Cash and cash equivalents as atthe b€ginning otlhe year (514.71) (14.31) 103.26 181.51 {83.49) 175.12 (167.92) (57.55) 175.12 Cash and cash equivalents as atthe end olthe year 88.95 91.63 107.47 Rsconclll.tion ol cash.nd c.rh equlv.lontr wlth tho Balance sheel Cash and c:sh equivalents as atth€ end ol the year unrealised loss / (sain) on foreign cunency cash and cash equivalerns 88 95 1.23 91.63 (1.82) 107 47 11.21) Cash and cash equivalenis restated balance as per balance sheet 90 18 E9 81 103 26 8 The Group op€rates exclusively in one reponable business segment r.e., "Pharmac€dicals" 9 The Financial Resulls are available lor inveslors at on the company's websile wv/w aiantaphama.com, ww.nseindia.com and a AR * By order or the Board r-r//"t'--z Z. i,lumbai 30 Oclober 2026 Corporate tdentity Number - L24230MH1979qLC022059 Registered ofiice:Ajanta Tower, 54-A, M vasanji Road, chakata, Andheri (E), Mumbai- 400 093. Tel.: +9'l-22-6060 gooo 063 t & I(,o T +91 22 6060 9000 E aplfinance@alantapharma.com W www.ajantapharma.com 67194 MUMBAI CedJd 6 c t Co.
Page 8
BSR&Co.LLP 14th Floor, Central B Vv]ng and North C Wng Nesco lT Park 4, Nesco Center Western Express Highway Goregaon (East), Mumbai - 400 063, India Telephone: +91 (22) 6257 10OO Fax +91 (22) 6257 1010 Chartered Accountants Limited Review Report on unaudited consolidated financial results of Ajanta Pharma Limited for the quarter ended 30 September 2026 and year to date results for the period from 1 April 2026 to 30 September 2026 pursuant to Regulation 33 of Securities and Exchange Board of lndia (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended To the Board of Directors of Ajanta Pharma Limited '1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Ajanta Pharma Limited (hereinafter referred to as "the Parent'), and its subsidiaries (the Parent and its subsidiaries together relerred to as "the Group') for the quarter ended 30 September 2026 and year to date results for the period from 'l April 2026 to 30 September 2026 Cthe Statement'), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of lndia (Listing Obligations and Disclosure Requirements) Regulations, 20'15, as amended ("Listing Regulations"). 2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in lndian Accounting Standard 34 "lnterim Financial Reponind ("lnd AS 34"), prescribed under Section '133 of the Companies Act, 2013, and other accounting principles generally accepted in lndia and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a crnclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of lnteim Financial lnfomation Peiormed by the lndependent Auditor of the Entlay'l issued by the lnstitute of Chartered Accountants of lndia. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matlers, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of lndia under Regulation 33(8) of the Listing Regulations, to the extent applicable. 4. The Statement includes the results of the following entities: lath Flod, C.nml a Wnl .nd NonhCWnt N.r@ lT P.d a NG@ c..t ., w.tt.m Expr.t! Fri$My Go6o.on (EG0. MumD.i-.00063 s. No. Nature of Component Relationship 1 Ajanta Pharma Limited Parent 2 Aianta Pharma (Mauritius) Limited Whollyowned subsidiary 3 Ajanta Pharma USA, lnc. Wholly owned subsidiary 4 Ajanta Pharma Philippines, lnc Wholly owned subsidiary Ajanta Pharma Nigeria Limited Wholly owned subsidiary BSR&Co (apanne.sh'p,imwthRegsralDnNo 8A61223)conven€dinloBSR!C..LLP(a Lim red L ablity PatueEhrp wnh LLP R.gistBtbn No aaa a13l ) uih .fi.ci rrcm octob.r 1,r 201 3 Page 1 ot 2 5 Y
Page 9
BSR&Co.LLP Limited Review Report (Continued) Ajanta Pharma Limited FoTBSR&Co.LLP Chaftered Accountants Firm's Registration No. :'l 01 248W/vV-'l 00022 1 I Mumbai 30 October 2026 Rekha Shenoy Paftner Membership No.: 124219 UDIN:261 2421 9OKQLNS1494 Page 2 of 2 5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid lndian Accounting Standard and olher accounting principles generally accepted in lndia, has not disclosed the informataon required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any malerial misstatement. 6. The Statement includes the interim financial information of 3 Subsidiaries which have not been reviewed, whose interim financial information reflects total assets (before consolidation adjustments) of Rs. 302.17 Crores as at 30 September 2026 and total revenues (before consolidation adjustments) of Rs. 92.40 Crores and Rs. 186.45 Crores , tolal net proflt / (loss) after tax (before consolidalion adjustments) of Rs. 8.94 Crores and Rs. (9.98) Crores and total comprehensive income (before consolidation adjustments) of Rs. 8.35 Crores and Rs. (11.11) Crores, for the quarter ended 30 September 2026 and for the period from 1 April 2026 to 30 September 2026 respectively, and cash flows (net) (before consolidation adjustments) of Rs 1.39 Crores for the period from 1 April 2026 to 30 September 2026 as considered in the Statement. According to the information and explanations given to us by the Parent's management, these interim llnancial information are not material to the Group. Our conclusion is not modilled in respect of this matter.
Page 10
@ phannaaianta Ajanta Pharma Limited Aianta Tower, 54-A, M V Road, Chakala, Andheri (E), Mumbai - 400 093, lndia T +91 22 6060 9000 E aplfinance@ajantapharma.com W www.ajantapharma.com Statement of Standalone Unaudited Financial Results for the quarter and six months ended 30 September 2026 ( in Crcre Greot Ploce To Work, Certified 30-Sep-26 30-Jun-26 30 Sep 25 3O-Sep-26 30-Sep-25 3i Mar26 Revenue f rom operetions Other income (R6rer nol6 3) 't,725 07 52 62 1,488 67 70 a2 1 .220 24 75 03 3.213.74 123.44 2 4ZO.AA 115.56 4.845 92 20144 'l,777.69 1.559-49 1,295.27 3,337.18 2,544.46 5,050.32 Erpon36a Cosl of matenab consumed Purcha3es of stock-inlrade Changes in ioventori6s of tinished goods, wod-in-progress and stock-in-irade Employee beneft s.xpense Depreciatbn and amodbation exp€ns€ Oher expenses (R€td nor€ 3) 348.97 74.43 (5.50) 355.14 079 46 30 435.94 296.51 57.20 (47 06) 352.81 076 43 31 122.51 217 60 51 89 2139 293 44 0.73 41.92 3.13 33 645.48 141.63 (s3 s6) 701 95 155 89 61 858 45 424.64 102.18 30.47 574.10 146 a2 23 67E,OE 916.52 218 06 (57 32) 1,194 05 259 164 77 1,376.62 973.30 2.391.11 r,893.50 3,819.29 522.62 158.54 (15 81) 423.45 101.63 635 321.97 65.97 6.17 946_07 26017 (9.46) 650.95 136.70 976 1,231.03 276 61 7.60 Not Profit for the poriod O$er Comprehon3ivo lncomo locll llems lhat will not b€ reclassfi€d subsequently lo proft or loss lncome tax relaling lo nems that will not be rcclassified to protll or loss 379 89 297 11.04) 315.47 (5.11) '1 79 249.53 a72 (0.25) 695.35 \2.'t4J 0.75 504.50 (4.27) 149 946.E2 (0 48) o.17 Othe. ComDrehensavc lncome for the vear. net of tax ,t_93 (3.32) 0.47 11.39) 12.7Al 10.31) Total Comprehonsivc lncome for the period 381_82 112.',l5 250.00 693.97 301.72 946.s1 Paid'up Equity Sharc Capital(Face value oll2 each) Olher Equity Eahinqs PerShare (Facevslue of{ 2 each) (a) Basic , in a (b) oaluled - in a 25 a7 30 40 30 37 25.07 25.25 25 22 25 07 19.98 '19 97 25 0T 55 65 55.60 25 A7 40 39 40 38 25.07 4.198.46 7579 7578 erprcssed an unmodined conclusion. The review reporl has been liled wilh the stock exchang€ and is available on companywebsile lndra (Listing Obligations and Disclosure Requtemenls) Regulalions. 2015, as amended 3 Other income / Olhere a in Cro€ 30-SeD-26 30-Jun-26 30-Seo-25 30-S€D-26 30-Serl25 31 Ma.26 ONidend lrom subsdEnes (in olherincome) 15 23 1521 15 23 36 68 36 68 Foreiqn exchanqe oain (in other income) 1a 66 50 47 41 52 69 13 4A A4 99 66 Foreon exchanoe loss (rn olher exoense) 10 61 16 19 40 95 26.80 66 10 103 04 2019.esult.gifaninc@aseinthepaidupsharecapitalbya46s00(previouspedod?47,050)andsecuritiesprchiumby?3,l7crores(p€vlouspenoda350crores). I ,o *t a Corporate Identity Number - 124230MH 1979P1C022059 Registered Office: Ajanta Towe( 54-A, M Vasanji Road, Chakala, Andheri (E), Mumbai- 400 093. Tel.: +91-22-6060 9000 I r,255.07 | 1,136.04 -)& Co.
Page 11
@ aianta pharma Ajanta Pharma Limited Ajanta Tower, 54-A, M V Road, Chakala, Andheri (E), Mumbai - 400 093, lndia T +91 22 6060 9000 E aplfinance@ajantapharma.com W www.ajantapharma.com 5. Statement of Standalone Assets and Liabilities (in Crcrc Greot Plqce To Work, Certilied 3GSep26 31,M6.25 ASSETS Property, planl and equipment Capilal work-in-progress Olher lntangible assels Olher l5nancial assets lncome lax assets (net) Olher non-cunenl assets 1780.01 326.55 7979 45.21 49.96 o.2a 92 57 1,722.6? 25E.05 8't.15 40.99 215.39 617 557 3711 lotal non-current assets T€de receivables Cash and cash €quivalenls Bank balances olher than cash and c€sh equivalenls Other nnancbl assets 2,380.50 845.29 588.09 1 475.51 7177 1.77 1 ,19 3.11 277 A3 2,r9E.06 44471 559.85 1,365.77 E9,OZI 1.51 1.68 E,9E 217 12 Assels classifed as hed for sae 3,268.19 3,rrE.65 Total current assets 3.256.19 3,118.66 5.648.69 5,3r6.72 EQUITYAND LIABILITIES Equity 25.07 500.66 25.07 198 46 on'curent liabilitie3 Other fi nancial liabililies Olher non-cunent liabildies Delerred lar liabililies (Nel) 4,525.73 24.12 2-5'l 1.50 75.20 107.73 4,223.53 29 5E 1.42 1-67 51.15 117 git Total Non-current liabilrtiei C u nont liabilitios (a) total outstanding dues ot micro and small enlerprises (b) lolal ouGt.nding dues ol crednors olherthan micrc and smallenlerpnses Oher fi nancial liabalilies Lease liabililies Other curent liabiliUes lncome tax liabilities (Net) 215.06 44.21 435 26 19321 606 121 60 32 3E 7514 ?0216 5417 417 68 259.19 5.11 119.00 30.39 5.49 Tot l curentiiabilities 907.90 891.03 Totalliabirirres '1,122.96 1,093.19 Total equity and liabililies 5.648.69 5,316.72 & Co L(A t Corporate ldentity Number - L24230MH1979PLC022059 Registered office: Ajanta Tower, 54-A, M Vasanji Road, chakala, Andheri (E), Mumbai- 400 093. Tel.: +91-22-6060 9000 I red nq
Page 12
@ aianta pharma Ajanta Pharma Limited Ajanta Tower, 54-A, N4 V Road, Chakala, Andheri (E), Mumbai - 400 093, lndia T +91 22 6060 9000 E aplfinance@ajantapharma.com W www.alantapharma.com 6. Statement ot Standalone Cash Flow < in Crore Greot Ploce To Work. Certified 30-SeF26 30-Setr25 31-Mar 26 A. Cash flow from ope.atng 3ctivities Deprecialion .nd amonbatun expense Loss /(gain) on sale / rctilement ol prop€rly, ptant and equipment (net) Dividend lrom subsidiaries Loss /(Gain) on investment at FWPL Gain on sale/€demption ol Cunent lnveshents lnleresl income on investlhenl and deposits Loss / (Gain) on fair value of dedvatjve Oelerred govemment granl Equily setlled share based payment Unreallsed foreign exchanqe loss /{sain) / loss on linancial assets 946 07 89.61 0.38 1.55 (1s.23) (0.32) (6 78) (28.81) {69.4E) (0.17) 8.10 34.21 650 96 82.23 052 1.46 (36.68) 0.35 {4 75) (23.281 66.10 (0.17) o.77 (30.82) 1.39 1,231.03 164 77 187 259 (36 68) (1 s5) (8.70) (51.04) 88 92 (0.33) '1.53 (56.14) 1.89 Oper.Ung cash flow b€ioro worting c.pital changes Changes rn wofijng cap'tal Oecrease / (increase) in trade rece,vables Dec.ease / (increase) in olher receivable Decrease / (increase) in invenlories Decrease / (increase) in trade payable lnclease / (decrease) in orher payable 963.16 llso 771 (30 33) {0.58) 9.16 (6.88) 24.63 708.18 44.62 161.42) 70 26 (16.r4) (75.19) (44.65) 1,340.15 177.61) (136.17) (10s.42) 103.69 (s 37) 122 39J Cash gon6ratcd from op€r.ting acuvitios Nei ncome lax paid 808.213 (185 86) 665.66 (1i6 60) 1,096.89 (293 06) Netcash g.nGrit€d from oFrating activitias B. C.sh llow hom invesling .ctvitios Capital exp€nditure on properly, planl and equipmenl & inlangible assels includang capdaladvances Proceeds lrcm sale ot property, planl and equipment Bank balances noi considered as cash and cash equivalents Dividend irom subsidiaries Purchase of cunenl inveslmenls Proceeds fiom sale ol curenl investments lncome on inveslmenls and deposns lnvestmenl in Privale Limned Com Noll Currenl lnvestmenl 622.57 (258.90) 042 (0.26) 15.23 (2,118 96) 2,097 A2 34'12 {3 s7) 549.06 1171.101 2.5E o.o2 36.6E (1,s60.86) 1,15r1.99 2015 803.83 p67.2Al 050 (0.12) 36 66 (2,659.98) 2,549.09 44.81 (3.26) Net cash used in investing.ctivities C. Cash flow from finanding rctivities Paymenl ol lease lrability (ncru&r int e, or Rr r .3 @Es rn @rc.i y€rr, Rs 1 35 @6r rn pEviery..r rn! Rr 2 7s@E. in FY 2026) Dividend paid (234_10) (0 07) (1.29\ (399.6r) (520.54) (0.11) (8.11) (0.01) (399.56) lo 27) (9.63) 1349 72) Net cash used in financing activities Net increase / (decreasel in cash and cash equivalents Cash and cash equivaenls as at the beglnn,ng oflhe year 1403.97) (15.501 89 04 (8.23) 20.29 48 60 (359.62) il,l.65 4E 60 Cash and cash equivalents as al lhe end olthe year 73.54 58.89 93.25 Reconcili.tion ofcash and cash equivalents vrith the Balanc€ sheet Cash and cash equivalenls as atthe end or the year Unreaised oss / (gain)on loreisn cuftency cash and cash equ vale.ts 7354 123 68.89 (1.82) 93 25 14 21) Cash and cash equivaenis restaled balance as per balance sheet 6l o7 a9 04 AR lt. By order of lhe aoard For Aj.nta Pharma L I =zt- Yogsh M. Aqrawal lvlanaging DireclorLlumbai 30 Oclober 2026 * Corporate ldentity Number - L24230MH1979PLC022059 Registered Office:Ajanta Tower, 54-A, M Vasanji Road, Chakala, Andheri (E), Mumbai- 400 093. Tel.: +91-22-6060 9000 M U IlI BAI lrq CE t & IIA t Co. dA 7 The Company operates exclusively in one reporlable business segment ie., "Pharmaceutjcals '. 8 The Financial Results a€ available for inveslors al on lhe company's website www.ajanlapharma com, ww nseindia com and www bseindia com.
Page 13
14th Floor, Central B Wng and North C Wng Nesco lT Park 4, Nesco Center Western Express Highway Goregaon (East), Mumbai - 400 063, lndia Telephone: +9'1 (22) 6257 1000 Fax. +91 122) 6257 1010 Chartered Accountants Limited Review Report on unaudited standalone financial results of Ajanta Pharma Limited for the quarter ended 30 September 2026 and year to date results for the period from 1 April 2026 to 30 September 2026 pursuant to Regulation 33 of Securities and Exchange Board of lndia (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended To the Board of Oirectors of Ajanta Pharma Limited 1. We have reviewed the accompanying Statement of unaudited standalone financial results of Ajanta Pharma Limited (hereinafter referred to as "the Company") for the quarter ended 30 September 2026 and year to date results for the period from 1 April 2026 to 30 Seplember 2026 ('the Statement"). 2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in lndian Accounting Standard 34"lnteim Financial Repoftind'("lnd AS 34"), prescribed under Section 133 of the Companies Act, 20'13, and other accounting principles generally accepted in lndia and in compliance with Regulation 33 of the Securities and Exchange Board of lndia (Listing Obligations and Disclosure Requirements) Regulalions,2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review. 3. We conducted our review ofthe Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of lnterim Financial lnformation Peiormed by the lndependent Auditor of the Enfibli issued by the lnstitute of Chartered Accountants of lndia. A review of interim financial information consasts of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as above, nothing has come to our attention lhat causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid lndian Accounting Slandard and other accounting principles generally accepted in lndia, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or lhat it contains any malerial misstatement. FoTBSR&Co.LLP Chaftered Accountants Firm's Registration No. :'l 01 248w/vv-1 00022 \, v. / Rekha Shenoy Paftnet Membership No.: 124219 u D lN. 26 1 242 1 qZZRY EX267 4 ralh Fbor, c.nr.lB !!lng &d No.rh c vwle, N.@ ll P.fia Ner@ crn r. v\b.i.m ElpE.. Hrchfy. Go..g.d (E.{, Mun$.i - a00063 Page 1 of 'l asReco {. o.ntch'o fim *,l R.gielEbd No 8161223r@n{tud'nbasRaco ttP(. L'd.d t '.bany P.'!D6h'p *th LL P R.gEhbF No. AAB-€ r 31) mh .i.d trDF Odob.r 1,1 2013 BSR&Co.LLP Mumbai 30 october 2026